Results 31 to 40 of about 40,685 (224)

Assessing the functional consequence of loss of function variants using electronic medical record & Large-Scale Genomics Consortium Efforts

Frontiers in Genetics, 2014
Estimates from large scale genome sequencing studies indicate that each human carries up to 20 genetic variants that are predicted to results in loss of function (LOF) of protein-coding genes.
Patrick eSleiman, Jonathan eBradfiled, Frank eMentch, Berta eAlmoguera, John eConnolly, Hakon eHakonarson   +5 more
doaj   +1 more source

HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox". [PDF]

, 2016
BackgroundProprotein convertase subtilisin kexin 9 (PCSK9) inhibitors reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes in the general population.
Deeks, Steven, Ganz, Peter, Grunfeld, Carl, Hsue, Priscilla Y, Hur, Sophia, Kohli, Payal, Ma, Yifei, Scherzer, Rebecca, Scott, Rob, Wasserman, Scott, Weigel, Bernard   +10 more
core   +1 more source

PCSK9 Inhibitor Use and Outcomes Using Concomitant Lipid-Lowering Therapies in the Veterans Health Administration

American Journal of Medicine Open, 2023
Background: Real-world data on use of PCSK9 inhibitors (PCSK9-Is), with or without statins and/or ezetimibe, and associated outcomes, can inform more effective prescribing.
Jessica Eloso, Asma Awad, Xinhua Zhao, Francesca E. Cunningham, Rongping Zhang, Diane Dong, Cathy Kelley, Peter A. Glassman, Sherrie L. Aspinall   +8 more
doaj   +1 more source

Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms

Arthritis Research & Therapy, 2021
Background Proprotein convertase subtilisin kexin 9 (PCSK9) targets the LDL-receptor (LDLR) which raises LDL-levels. In addition, PCSK9 has proinflammatory immunological effects.
Johan Frostegård, Sabbir Ahmed, Ingiäld Hafström, Sofia Ajeganova, Mizanur Rahman   +4 more
doaj   +1 more source

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah, Bridges, Ian, Cheng, Lung-I, Dent, Ricardo, Deshpande, Sohan, Forbes, Carol A., Gandra, Shravanthi R., Kleijnen, Jos, Ross, Janine, Sattar, Naveed, Stroes, Erik S.G., Toth, Peter P., Worth, Gavin M., Worthy, Gillian   +13 more
core   +1 more source

Clinical exome performance for reporting secondary genetic findings. [PDF]

, 2014
BACKGROUND : Reporting clinically actionable incidental genetic findings in the course of clinical exome testing is recommended by the American College of Medical Genet- ics and Genomics (ACMG).
Clark, P, Fortina, Paolo, Kricka, Lj, Londin, E, Park, J. Y., Park, Jy, Sponziello, Marialuisa   +6 more
core   +1 more source

Increased serum PCSK9 levels are associated with renal function impairment in patients with type 2 diabetes mellitus

Renal Failure, 2023
Purpose The purpose of this study was to investigate the association between serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels and renal function impairment in type 2 diabetes mellitus (T2DM) patients.Methods PCSK9 levels were measured ...
Zhicai Feng, Xiangyu Liao, Hao Zhang, Juan Peng, Zhijun Huang, Bin Yi   +5 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 is a psoriasis-susceptibility locus that is negatively related to IL36G

JCI Insight, 2022
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses.
Alexander Merleev, Antonio Ji-Xu, Atrin Toussi, Lam C. Tsoi, Stephanie T. Le, Guillaume Luxardi, Xianying Xing, Rachael Wasikowski, William Liakos, Marie-Charlotte Brüggen, James T. Elder, Iannis E. Adamopoulos, Yoshihiro Izumiya, Annie R. Leal, Qinyuan Li, Nikolay Y. Kuzminykh, Amanda Kirane, Alina I. Marusina, Johann E. Gudjonsson, Emanual Maverakis   +19 more
doaj   +1 more source

Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study

BMC Emergency Medicine, 2023
Objectives Pro-protein convertase subtilisin/kexin 9 (PCSK9) decreases the clearance of the pathogenic lipids, supporting the potential role of PCSK9 in the prognosis of sepsis.
Yuanlu Shu, Ziwei Deng, Ye Deng, Jianliang Zhou, Jin Wang, Zhenxing Duan, Tao Jiang, Xiang Zhao, Zhihua Shi, Chengfeng Qiu   +9 more
doaj   +1 more source

Suppressor of Cytokine Signaling-3 (SOCS-3) induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) expression in hepatic HepG2 cell line [PDF]

, 2015
The suppressor of cytokine signaling (SOCS) proteins are negative regulators of the JAK/STAT pathway activated by proinflammatory cytokines, including the tumor necrosis factor (TNF-\u3b1).
Corsini, Alberto, Cristofani, Riccardo, Ferri, Nicola, Liu, Jingwen, Macchi, Chiara, Magni, Paolo, Ricci, Chiara, Ruscica, Massimiliano   +7 more
core   +2 more sources